Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline Review, H2 2017’, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Marburg Hemorrhagic Fever)

The report reviews pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Marburgvirus Infections (Marburg Hemorrhagic Fever) therapeutics and enlists all their major and minor projects

The report assesses Marburgvirus Infections (Marburg Hemorrhagic Fever) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Marburgvirus Infections (Marburg Hemorrhagic Fever) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Arno Therapeutics Inc

BioCryst Pharmaceuticals Inc

Eisai Co Ltd

Emergent BioSolutions Inc

Fab'entech SA

Integrated BioTherapeutics Inc

Johnson & Johnson

NanoViricides Inc

Profectus BioSciences Inc

Rodos BioTarget GmbH

Sarepta Therapeutics Inc

Theravectys SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Overview

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Companies Involved in Therapeutics Development

Arno Therapeutics Inc

BioCryst Pharmaceuticals Inc

Eisai Co Ltd

Emergent BioSolutions Inc

Fab'entech SA

Integrated BioTherapeutics Inc

Johnson & Johnson

NanoViricides Inc

Profectus BioSciences Inc

Rodos BioTarget GmbH

Sarepta Therapeutics Inc

Theravectys SA

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Drug Profiles

(Ebola + Marburg) (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Ebola + Marburg) (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Ebola + Marburg) (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

1-E703 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies for Ebola and Marburg Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARD-5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVI-7288 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eritoran tetrasodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FDX-000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galidesivir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GreEMTri - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infectious disease vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MR-191N - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MR-78 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-026 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBT-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Ebola and Marburg Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Ebola and Marburg Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit VP40 for Ebola and Marburg Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAC-69120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products

Marburgvirus Infections (Marburg Hemorrhagic Fever) - Product Development Milestones

Featured News & Press Releases

Jan 19, 2016: Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial

Nov 17, 2015: Profectus Presents Preclinical Data Demonstrating that a Single Dose of Multi-Component Vaccine Provides Complete Protection Against Zaire and Sudan Species of Ebola Virus and Marburg Virus

Jul 22, 2015: Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplus platform

May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research

Apr 08, 2015: Profectus BioSciences Ebola Vaccine Shown Effective and Safe in Providing Rapid, Single-Dose Protection Against Current "Makona" Ebola Outbreak Strain in Non-Human Primates

Mar 31, 2015: BioCryst Awarded BCX4430 Advanced Development Contract

Mar 25, 2015: IBT Presents Pan-Ebola and Pan-Filovirus Monoclonal Antibodies

Jan 22, 2015: NanoViricides Reports That It Has Shipped anti-Ebola Drug Candidates For Testing to a BSL-4 Hi-Security Biocontainment Laboratory

Dec 23, 2014: BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection

Oct 31, 2014: Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses

Oct 27, 2014: NanoViricides Signs CRADA for Material Transfer with USAMRIID for Evaluating Its Anti-Ebola Drug Candidates

Sep 18, 2014: BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases

Jul 31, 2014: UTMB researchers receive over $6 million to develop treatment for deadly Ebola and Marburg viruses

Feb 10, 2014: Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate

Sep 17, 2013: BioCryst Awarded Contract by the National Institute of Allergy and Infectious Diseases to Develop BCX4430 for the Treatment of Marburg Virus Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Arno Therapeutics Inc, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by BioCryst Pharmaceuticals Inc, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Eisai Co Ltd, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Emergent BioSolutions Inc, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Fab'entech SA, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Integrated BioTherapeutics Inc, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Johnson & Johnson, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by NanoViricides Inc, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Profectus BioSciences Inc, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Rodos BioTarget GmbH, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Sarepta Therapeutics Inc, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Pipeline by Theravectys SA, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Dormant Projects, H2 2017

Marburgvirus Infections (Marburg Hemorrhagic Fever) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports